1,502 results on '"Verma A"'
Search Results
2. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
3. SKI controls MDS-associated chronic TGF-β signaling, aberrant splicing, and stem cell fitness
4. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies
5. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
6. Stem and progenitor cell alterations in myelodysplastic syndromes
7. Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations
8. Hypomethylating Agent Maintenance for Favorable and Intermediate Risk Acute Myeloid Leukemia
9. Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
10. Outcomes of Autologous Stem Cell Transplantation for Relapsed DLBCL in Single Center Serving a Minority Population
11. Trends in Collection and Utilization of Autologous Hematopoietic Stem Cells (APBHC) Intended for Transplant in Patients with Multiple Myeloma
12. An Observational Prospective Study of Dasatinib 50mg Daily As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia Patients in Chronic Phase
13. Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
14. Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
15. Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition
16. Outcomes Analysis of T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL) in a Minority Rich Cohort
17. Dietary iron restriction protects against vaso-occlusion and organ damage in murine sickle cell disease
18. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas
19. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome
20. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
21. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
22. Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21
23. Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation
24. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
25. A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort
26. Barriers to Autologous Stem Cell Transplantation As Consolidation for Primary Central Nervous System Lymphoma (PCNSL) in HIV Positive Patients in a Minority Rich Cohort in the Bronx, New York
27. Acute Clinical Syndrome of HLH in Patients with Hematologic Malignancy and EBV Infection
28. Dietary Iron Restriction Alters Microbiota-Host Crosstalk and Protects Against Vaso-Occlusion and Organ Damage in Sickle Cell Disease Mice
29. Characterization of Real-World Chronic Graft-Versus-Host-Disease Patients Receiving Belumosudil
30. Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition
31. Outcomes of Autologous Stem Cell Transplantation for Relapsed DLBCL in Single Center Serving a Minority Population
32. Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial
33. Outcomes Analysis of T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL) in a Minority Rich Cohort
34. Adult T-Cell Leukemia/Lymphoma Diagnosed in North American Is Characterized By a Requirement for BCL6 and a Cell Cycle Program Associated with DNA Replication Stress
35. Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
36. Trends in Collection and Utilization of Autologous Hematopoietic Stem Cells (APBHC) Intended for Transplant in Patients with Multiple Myeloma
37. Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia
38. Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML
39. Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS: Assessment of Leukemia Stem Cell Eradication By High-Resolution MRD Assay
40. Autologous Stem Cell Transplantation (ASCT) Improves Survival Outcome in Primary Central Nervous System Lymphoma (PCNSL) in a Minority Rich, Underserved Inner City Population in the Real-World Setting
41. Hypomethylating Agent Maintenance for Favorable and Intermediate Risk Acute Myeloid Leukemia
42. An Observational Prospective Study of Dasatinib 50mg Daily As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia Patients in Chronic Phase
43. Blocking T Cell Co-Stimulation Via CD70 As a Target for Gvhd in Allogeneic Stem Cell Transplantation (SCT)
44. Serum Protein Markers of Survival, Relapse and GvHD Identified within the First Two Weeks Post Stem Cell Transplantation
45. Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
46. Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib
47. Iron Chelation Improves Ineffective Erythropoiesis and Iron Overload in a Mouse Model of Myelodysplastic Syndrome
48. Factors Associated with Early Mortality in Patients with Multiple Myeloma: A SEER Analysis
49. Managing Childhood Immune Thrombocytopenia in a Government Facility in India; Perspective from an LMIC
50. Therapeutic Gene Editing of HSCs Ex Vivo without in Vitro Culture Avoids Genotoxicity, Simplifies Procedures, and Preserves Efficiency and Stemness
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.